PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Despite missing primary efficacy endpoint, ATOMIC-AHF identifies positive trends

Hot Line IV: Late-breaking trials on heart failure and acute coronary syndrome

2013-09-03
(Press-News.org) AMSTERDAM, The Netherlands – Omecamtiv mecarbil, a cardiac myosin-activator, did not achieve its primary efficacy endpoint in reducing dyspnoea (shortness of breath) in patients with acute heart failure, according to the results of the phase II ATOMIC-AHF (Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure) study.

However, a cohort which received the highest dose of the drug showed greater dyspnoea relief compared with placebo, and there were also other favourable dose and concentration-related trends, noted lead investigator John R. Teerlink, MD, Professor of Clinical Medicine at the University of California San Francisco and Director of Heart Failure at the San Francisco Veterans Affairs Medical Center, USA.

"The study was a real success for its purpose, as a dose-finding, safety and tolerability study," he said. "The main objective of ATOMIC-AHF was to investigate the pharmacokinetics and tolerability of intravenous omecamtiv mecarbil in the acute heart failure (AHF) population, and like most Phase II studies, it was not powered or designed around the efficacy endpoint," he explained.

"We are pleased to see as much efficacy signal as was apparent, and the study provides essential data to inform the dosing regimen for future Phase 3 trials of the intravenous formulation."

ATOMIC-AHF enrolled 613 patients with left ventricular systolic dysfunction who were acutely hospitalised with dyspnoea at rest or minimal exertion.

The subjects, from 106 sites in North America, Europe and Australia, were randomly assigned to receive 48 hours of intravenous placebo or omecamtiv mecarbil (OM) in 3 ascending dose cohorts designed to achieve plasma concentrations of 115, 230, and 310 ng/mL.

The primary efficacy endpoint was the effect on dyspnoea at 6, 24 and 48 hours, with secondary endpoints of safety, tolerability, pharmacokinetics, and echocardiographic indices of cardiac function.

Compared to the pooled placebo groups the OM groups showed no statistically significant difference in dyspnoea symptoms (P = 0.33) - therefore, the primary endpoint was not met, said Prof. Teerlink,

However, in the cohort with the highest OM dose there was a trend towards greater response compared to its paired placebo group (51% vs 37%, P = 0.03), along with significant dose-related and plasma concentration-related trends in response (P = 0.025 and P = 0.007, respectively).

Additionally, there were significant (P < 0.001) concentration-related increases in systolic ejection time, which is the echocardiographic signature of OM, said Prof. Teerlink.

"Unlike prior agents that increased intracellular cAMP and calcium and decrease ejection time, omecamtiv mecarbil's unique mechanism of action prolongs ejection time, allowing for increased stroke volume without significantly increased myocardial oxygen consumption," he said. "This effect has been remarkably reproducible from healthy dogs, dogs with heart failure, healthy human volunteers, and patients with both chronic, and now in ATOMIC-AHF, acute heart failure."

As seen in previous studies, OM produced significant reductions in heart rate (P < 0.001) without decreasing systolic blood pressure, said Prof. Teerlink.

There were also trends toward reductions in worsening heart failure, reduced incidence of supraventricular arrhythmias, and no increase in ventricular arrhythmias.

"None of these outcomes should be considered confirmed, since that was not the intent of the study, but the trends are very encouraging, especially for a trial of its size and scope," he said, adding that adverse events, including adjudicated deaths and rehospitalisations were "indistinguishable" from placebo.

There were 7 post-randomization myocardial infarctions in the omecamtiv mecarbil treated groups compared with 3 in placebo treated groups (2.3% vs 1.0% respectively). There was a modest increase in cardiac troponin I in OM-treated patients, but no evidence to suggest this was linked to increasing OM concentrations, "however, we will be vigilant about studying the ATOMIC-AHF data for possible explanations."

"One of the greatest challenges of the ATOMIC-AHF trial has been managing expectations, explained Prof. Teerlink. "Omecamtiv mecarbil is probably one of the most interesting new chemical entities in cardiovascular medicine now and consequently, expectations are very high in the scientific and lay communities. Physicians have struggled for decades to develop agents that improve cardiac function without increasing arrhythmias or mortality; omecamtiv mecarbil has the potential to be such an agent."

###

SOURCES OF FUNDING : The ATOMIC-AHF study was funded by Amgen Inc.

DISCLOSURES: Dr. Teerlink has received research grants and/or consulting fees from Amgen, Corthera, Cytokinetics, Merck, Novartis, Sorbent, and Trevena Unlabeled/unapproved uses disclosure: Use of omecamtiv mecarbil in patients with heart failure is investigational.

NOTE TO EDITORS About the European Society of Cardiology The European Society of Cardiology (ESC) represents more than 80 000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.

About ESC Congress 2013 The ESC Congress is currently the world's premier conference on the science, management and prevention of cardiovascular disease. The spotlight of this year's event is "The Heart Interacting with Systemic Organs". ESC Congress 2013 takes place from 31 August to 4 September at the RAI centre in Amsterdam, Netherlands. More information is available from the ESC Press Office at press@escardio.org

END



ELSE PRESS RELEASES FROM THIS DATE:

Hot Line IV: Late-breaking trials on heart failure and acute coronary syndrome

2013-09-03
AMSTERDAM, The Netherlands – The blood pressure lowering drug aliskiren did not improve coronary artery disease when given to patients who had prehypertension, results of the Aliskiren Quantitative Atherosclerosis Regression Intravascular Ultrasound Study (AQUARIUS) reveal. The findings, reported at the European Society of Cardiology Congress with simultaneous publication in the Journal of the American Medical Association, offer new insight into the value of lowering blood pressure beyond prehypertensive goals, suggested lead investigator Stephen Nicholls MBBS, PhD, Deputy ...

TAVI is safe alternative to redo cardiac surgery

2013-09-02
Use of bioprosthetic heart valves has dramatically increased (from 18% in 1991 to 59% in 2003), mainly in older patients with comorbidities. This is due to the increased risk of bleeding complications associated with lifelong use of anticoagulation for mechanical prostheses. But structural valve deterioration is one the main complications associated with bioprosthetic heart valves. In large registries including more than 300 000 patients undergoing aortic valve replacement the reoperation rate for patients receiving a bioprosthesis was 3.1% at 11-13 years of follow-up ...

Women less likely to die after TAVI than men

2013-09-02
Dr Sherif said: "Earlier studies on the impact of gender on outcome after transcatheter aortic valve implantation (TAVI) have had conflicting results. A Canadian study reported in 641 consecutive patients that female sex is associated with a better long-term and short-term survival after TAVI.1 An Italian study of 305 high risk patients found no gender differences in composite safety and efficacy endpoints at 30 days and one year after TAVI."2 The current analysis examined gender differences in outcomes for 1432 consecutive patients from 27 centers who were enrolled in ...

TAVI feasible in bicuspid aortic valve

2013-09-02
Bicuspid aortic valve (BV) is the most common congenital valvular abnormality, occurring in 1-2% of the general population. Two of the aortic valvular leaflets fuse during development resulting in a valve that is bicuspid instead of the normal tricuspid configuration. BV is associated with increased mechanical stress which predisposes to calcification and development of aortic stenosis which narrows the opening of the aortic valve. Dr Bauer said: "TAVI is used to treat elderly high risk patients with severe aortic stenosis. Despite previous assumptions the frequency of ...

Health of older women in developed countries continues to improve

2013-09-02
Measures taken in developed countries to reduce noncommunicable diseases – the leading causes of death globally – have improved the life expectancy of women aged 50 years and older over the last 20 to 30 years. But, according to a study that will be published in the Bulletin of the World Health Organization on 2 September, the gap in life expectancy between such women in rich and poor countries is growing. The WHO study, one of a collection of articles in a special issue of the journal devoted to women's health beyond reproduction, found that the leading causes of death ...

Stomach bacteria switch off human immune defences to cause disease

2013-09-02
Helicobacter pylori is a bacterium that establishes a life-long stomach infection in humans, which in some cases can lead to duodenal ulcers or stomach cancer. New research, presented at this week's Society for General Microbiology Autumn Conference, gives us a clearer understanding of how these bacteria can manipulate the human immune system to survive in the mucosal lining of the stomach. Researchers from the University of Nottingham have shown that H. pylori is able to supress the body's normal production of 'human beta defensin 1' (hβD1), an antimicrobial factor ...

Scientists discover novel functions of platelets

2013-09-02
OKLAHOMA CITY, September 1, 2013 — A new finding could lead to novel treatments to reduce bleeding in trauma and severe infections. The research, from Oklahoma Medical Research Foundation scientists Lijun Xia, M.D., Ph.D., Jianxin Fu, M.D., Ph.D., and Brett Herzog, Ph.D., appears in the most recent issue of the journal Nature. One way the immune system keeps a body healthy is through immune surveillance. Lymphocytes, a type of white blood cell, constantly exit the bloodstream and "check in" at the lymph nodes to learn about possible pathogens or abnormal cell growth. ...

Spread of crop pests threatens global food security as Earth warms

2013-09-02
A new study has revealed that global warming is resulting in the spread of crop pests towards the North and South Poles at a rate of nearly 3 km a year. The study, published in the journal Nature Climate Change and carried out by researchers at the University of Exeter and the University of Oxford, shows a strong relationship between increased global temperatures over the past 50 years and expansion in the range of crop pests. Currently 10-16% of global crop production is lost to pests. Crop pests include fungi, bacteria, viruses, insects, nematodes, viroids and oomycetes. ...

Researchers untangle genetics of drug resistant TB

2013-09-02
For years, physicians around the world have watched as strain after strain of the deadly bacteria Mycobacterium tuberculosis evolves resistance to drugs. Over the last few decades researchers have used the tools of molecular biology to identify a handful of individual mutations that allow TB to withstand many of the key therapeutics that doctors use to treat it. These genetic markers serve as clues for new drug development and as tools for diagnosing drug-resistant strains of TB. But the pace of discovery has proven too slow in the face of the complex array of rapidly ...

Mycobacterium tuberculosis: Our African follower for over 70,000 years!

2013-09-02
Tuberculosis (TB) remains one of deadliest infectious diseases of humans, killing 50% of individuals when left untreated. Even today, TB causes 1-2 million deaths every year mainly in developing countries. Multidrug-resistance is a growing threat in the fight against the disease. An international group of researchers led by Sebastien Gagneux from the Swiss Tropical and Public Health Institute (Swiss TPH) has now identified the origin in time and space of the disease. Using whole-genome sequencing of 259 Mycobacterium tuberculosis strains collected from different parts ...

LAST 30 PRESS RELEASES:

Predictable structures in music synchronises blood pressure the most, and could be used to create personalized music-based cardiovascular therapies  

New systematic review and meta-analysis shows an association between shingles vaccination and lower risk of heart attack and stroke 

Food for thought: Using food delivery services to provide rapid cardiac arrest response and potentially save lives

College drinking linked to poor academics, mental health for those around the drinker: Study

Nearly 80% of whale sharks in this marine tourism hotspot have human-caused scars

Spider uses trapped fireflies as glowing bait to attract more prey

How AI can build bridges between nations, if diplomats use it wisely

80% of Americans don’t know early-stage prostate cancer often has no symptoms

Researchers engineer ureter tissue from stem cells, paving way for transplantable kidneys

Strong, evidence-based leadership at CDC essential in wake of director’s exit, says SHEA

Birdwatching tourism is booming. Some countries are benefiting, while others are left behind

High protein or Trp diet increases the risk of cancer-associated venous thromboembolism

Risk of a second cancer after early breast cancer is low

Genetic key to why immune responses differ between men and women

Discovery could lead to new treatments for life-threatening allergic reactions

CRF announces TCT 2025 late-breaking clinical trials and science

Ancient DNA reveals farming spread through migration, locals slow to adopt it

Researchers turn mouse scalp transparent to image brain development

New research reveals longevity gains slowing, life expectancy of 100 unlikely

Wheat that makes its own fertilizer

Certain communities of pond plants may increase greenhouse gases

Hormone therapy type matters for memory performance after menopause

Stroke risk highest among Native Hawaiian, Pacific Islander people

Scientists reveal warped protoplanetary discs, reshaping ideas about how planets form

Be it feast or famine, orangutans adapt with flexible diets

Insomnia patients report better sleep when taking cannabis-based medical products

Intrusive distracting thoughts may be associated with anxiety and linked to lower well-being, and occur more often when alone than in company

New crocodile-relative “hypercarnivore” from prehistoric Patagonia was 11.5ft long and weighed 250kg

“Unhappiness hump” in aging may have disappeared worldwide

Breathwork can induce altered states of consciousness linked with changes in brain blood flow

[Press-News.org] Despite missing primary efficacy endpoint, ATOMIC-AHF identifies positive trends
Hot Line IV: Late-breaking trials on heart failure and acute coronary syndrome